Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2023; 15(1): 143-154
Published online Jan 15, 2023. doi: 10.4251/wjgo.v15.i1.143
Published online Jan 15, 2023. doi: 10.4251/wjgo.v15.i1.143
Short-term efficacy and influencing factors of conventional chemotherapy combined with irinotecan in patients with advanced gastric cancer
Jun-Ping Wang, Jian-Lei Du, Ya-Ying Li, Pharmacy Department, Zhumadian Central Hospital, Zhumadian 463000, Henan Province, China
Author contributions: Wang JP design the experiment; Wang JP, Du JL and Li YY drafted the work; Du JL and Li YY collected the data; Wang JP and Du JL analysed and interpreted data; Wang JP, Du JL and Li YY revised and proofed the manuscript.
Institutional review board statement: The study was reviewed and approved by the Zhumadian Central Hospital Institutional Review Board (Approval No. 2022083).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: There is no conflict of interest.
Data sharing statement: All data and materials are available from the corresponding author.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jun-Ping Wang, BSc, Pharmacist, Pharmacy Department, Zhumadian Central Hospital, No. 747 West Section of Zhonghua Road, Zhumadian 463000, Henan Province, China. wangjp2023@163.com
Received: November 14, 2022
Peer-review started: November 14, 2022
First decision: November 30, 2022
Revised: December 6, 2022
Accepted: December 21, 2022
Article in press: December 21, 2022
Published online: January 15, 2023
Processing time: 57 Days and 8.6 Hours
Peer-review started: November 14, 2022
First decision: November 30, 2022
Revised: December 6, 2022
Accepted: December 21, 2022
Article in press: December 21, 2022
Published online: January 15, 2023
Processing time: 57 Days and 8.6 Hours
Core Tip
Core Tip: Gastric cancer is a malignant tumor of gastric mucosal epithelial cells with early symptoms not obvious, and most patients are advanced at the stage of diagnosis. Surgery, radiotherapy, and chemotherapy are often used in clinical treatment. Although chemotherapy is one of the main treatment options, there is no unified or standardized treatment method; therefore, it is particularly important to determine the effective treatment options for patients with advanced gastric cancer. This study explores the short-term efficacy and influencing factors of irinotecan combined with oxaliplatin and fluorouracil in patients with advanced gastric cancer.